Dasatinib was approved for the treatment of several forms of leukaemia, including CML, due to its capacity to inhibit BCR-ABL-positive cancers, and it is undergoing evaluation for use in lymphomas, breast, prostate and other cancers in clinical trials. This evidence concerns the gene ABL1 and cancer.